Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Get Free Report) Director Sangeeta N. Bhatia sold 646 shares of the business's stock in a transaction on Friday, August 30th. The stock was sold at an average price of $500.00, for a total value of $323,000.00. Following the sale, the director now directly owns 4,435 shares in the company, valued at $2,217,500. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Vertex Pharmaceuticals Stock Performance
VRTX opened at $478.57 on Thursday. The company has a market cap of $123.52 billion, a PE ratio of 31.06 and a beta of 0.40. The stock has a 50-day moving average of $483.40 and a 200-day moving average of $447.92. Vertex Pharmaceuticals Incorporated has a 52-week low of $340.83 and a 52-week high of $510.64. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.26 and a current ratio of 2.52.
Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its quarterly earnings results on Thursday, August 1st. The pharmaceutical company reported ($12.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($12.54) by ($0.29). The company had revenue of $2.65 billion for the quarter, compared to the consensus estimate of $2.66 billion. Vertex Pharmaceuticals had a negative return on equity of 2.45% and a negative net margin of 4.74%. The business's revenue was up 6.1% compared to the same quarter last year. During the same quarter last year, the company posted $3.53 EPS. As a group, equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post -1.85 earnings per share for the current fiscal year.
Institutional Trading of Vertex Pharmaceuticals
The $15 "Insider Secret" That Could Save Your Retirement
From Behind the Markets | Ad
What if I told you there's a $15 stock that a billionaire insider just poured $47 MILLION into?
That's right. You can grab shares of this potential retirement-maker for less than you'd pay for lunch.
Click here to discover the name and ticker of this "$15 billionaire-backed retirement stock" >>>
Large investors have recently made changes to their positions in the stock. University of Texas Texas AM Investment Managment Co. bought a new stake in shares of Vertex Pharmaceuticals during the 4th quarter worth about $25,000. GHP Investment Advisors Inc. bought a new stake in Vertex Pharmaceuticals during the 2nd quarter valued at approximately $29,000. Annapolis Financial Services LLC bought a new stake in Vertex Pharmaceuticals during the 1st quarter valued at approximately $27,000. Stephens Consulting LLC bought a new stake in Vertex Pharmaceuticals during the 2nd quarter valued at approximately $31,000. Finally, ICA Group Wealth Management LLC bought a new stake in Vertex Pharmaceuticals during the 4th quarter valued at approximately $28,000. Institutional investors own 90.96% of the company's stock.
Analysts Set New Price Targets
A number of equities research analysts have recently issued reports on the company. Guggenheim boosted their target price on Vertex Pharmaceuticals from $450.00 to $558.00 and gave the stock a "buy" rating in a research report on Friday, August 2nd. Argus upped their price target on Vertex Pharmaceuticals from $465.00 to $550.00 and gave the company a "buy" rating in a research report on Monday, June 17th. Barclays lowered Vertex Pharmaceuticals from an "overweight" rating to an "equal weight" rating and upped their price target for the company from $472.00 to $509.00 in a research report on Monday, August 5th. Redburn Atlantic began coverage on Vertex Pharmaceuticals in a research report on Thursday, June 27th. They set a "buy" rating and a $545.00 price target on the stock. Finally, TD Cowen upped their price target on Vertex Pharmaceuticals from $450.00 to $500.00 and gave the company a "buy" rating in a research report on Tuesday, July 23rd. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and sixteen have issued a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $485.91.
Read Our Latest Analysis on VRTX
About Vertex Pharmaceuticals
(
Get Free Report)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
